Major Strategic Initiatives Completed During Q3:
- Closed sale of Rx business for $1.6B
- Announced Acquisition of HRA Pharma for €1.8B
- Settled €1.6B Irish Tax Assessment for Net Cash Outlay of €266M
- Awarded €355M From Belgium Arbitration Decision
Supply Chain Disruption and Higher Input Costs Negatively Impact Q3 Results
2021 Financial Guidance Lowered
U.S. & European Consumer Self-Care Demand Robust and Accelerating
https://finance.yahoo.com/news/perrigo-reports-third-quarter-2021-113000431.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.